Abilify is a medication classified as an atypical antipsychotic and antidepressant.
Is also known as Aripiprazole
- Clinical Depression
- Bipolar Disorder
Approved by the FDA in 2002 for schizophrenia
For Mixed Episodes and Acute Manic of Bipolar Disorder in 2004.
Approved for use in combination with other drugs for Major Depressive Disorder in 2007.
- Approved for ages 10 – 17
- Approved for Adults
Mechanism of action
- Acts as a D2 partial agonist and 5-HT1A receptor, and like other atypical is a partial agonist of 5-HT2A receptor
- Half life of 75 hours
- 14 days are typical for the proper amount of concentration to be found within the plasma
- Blurred vision
Rarely seen side effects are:
- Tardive dyskinesia
- Blood sugar changes
- Allergic reaction
** – occasionally dosing may need adjustment with the above medications